In 2022, over 24k Aussie males were diagnosed with prostate cancer. One of the most commonly diagnosed cancers, it was also the third most common cause of cancer death in Australia in 2020. Its high prevalence and the cocktail of concerns that come with it have prompted the need for better diagnosis mechanisms than the
Read More
It may soon be easier for prostate cancer to be diagnosed at an early stage with Telix Pharmaceuticals (ASX: TLX) having submitted their radiopharmaceutical imaging technology to the Food and Drug Administration for approval. The New Drug Application (NDA) comes after completing clinical trials across more than 600 patients which builds on peer-reviewed clinical research
Read More